Pharmaceutical

GSK Pharmaceuticals reported a 29 percent year-on-year increase in net profit for the third quarter, with earnings reaching Rs 296 crore, driven by steady growth in its core therapeutic portfolio and improved operational efficiency. The performance reflects resilient domestic demand, effective cost management, and continued traction in key prescription segments. Revenue expansion and margin stability supported the bottom line, even as the broader pharmaceutical sector navigates pricing pressures and regulatory oversight.

Natco Pharma has received approval from the United States Food and Drug Administration (USFDA) for its latest oncology drug, marking a significant milestone in the company’s global expansion strategy. The approval not only underscores Natco’s research and development capabilities but also enhances access to cutting-edge cancer therapies in international markets. Industry experts note that the USFDA nod opens a substantial revenue stream for the Hyderabad-based firm while reinforcing India’s position in the global pharmaceutical landscape.

Shares of Sun Pharmaceutical Industries surged after the company reported a strong earnings performance, reinforcing investor confidence in its growth trajectory and operational execution. The results highlighted improved margins, steady revenue expansion, and disciplined cost management across key markets. Market participants responded positively to the outlook, viewing the numbers as evidence of resilience amid pricing pressures and regulatory challenges in the global pharmaceutical industry.

Piramal Pharma Ltd. reported a consolidated net loss of Rs 136 crore for the third quarter, as inventory-related challenges and cost pressures weighed on financial performance. Despite steady operational activity across its contract development and manufacturing services and consumer healthcare segments, elevated inventory levels and associated expenses eroded profitability. The results prompted a cautious response from investors, highlighting concerns over near-term earnings visibility.

Two of India’s largest pharmaceutical companies have initiated product recalls in the United States following observations flagged by the U.S. Food and Drug Administration, drawing attention to the growing regulatory pressure on global generic drug manufacturers. The recalls, described as precautionary and limited in scope, involve specific batches distributed in the U.S. market. While neither company reported widespread safety incidents, the action underscores the strict compliance environment governing pharmaceutical exports.

Sun Pharmaceutical Industries Ltd. has received regulatory approval from India’s drug regulator to manufacture and market a generic version of semaglutide, a breakthrough molecule used in the treatment of obesity and type 2 diabetes. The clearance positions India’s largest drugmaker to enter one of the fastest-growing therapeutic segments globally once patent protections expire. The decision underscores the regulator’s growing focus on improving access to advanced metabolic therapies while intensifying competition in the domestic pharmaceutical market.

Zydus has expanded its oncology offerings with the launch of a new biosimilar aimed at improving access to cancer treatment. The development marks a strategic step in the company’s efforts to deliver cost-effective, high-quality biologic therapies to patients. By introducing the biosimilar, Zydus seeks to address the growing demand for affordable oncology drugs amid rising cancer incidence and escalating treatment costs.

Pharma major Lupin has entered a strategic licensing agreement to manufacture and commercialize injectable Semaglutide, a leading therapy for type 2 diabetes, positioning itself to capitalize on the rapidly growing global diabetes treatment market. The deal aligns with Lupin’s broader strategy to strengthen its specialty care portfolio while leveraging its manufacturing and regulatory expertise. Analysts suggest this move could drive revenue growth, diversify product offerings, and enhance the company’s presence in high-margin therapeutic areas.

Sun Pharmaceutical Industries has expanded its presence in the global oncology space with the launch of a new skin cancer treatment, Unloxcyt, in the United States. The introduction marks a strategic milestone for India’s largest drugmaker as it deepens its focus on specialty and complex therapies in regulated markets. The drug targets a specific segment of skin cancer patients and reflects Sun Pharma’s sustained investment in research, development, and regulatory approvals. Industry experts view the launch as a calculated move to strengthen the company’s U.S.

Obesity-focused medications are rapidly becoming a defining growth driver for the global pharmaceutical industry, with Indian drugmakers positioning themselves to capture a share of this expanding market. Rising lifestyle-related disorders, increasing awareness of metabolic health and growing affordability are reshaping treatment demand. Sun Pharma, India’s largest drug manufacturer by market value, is among the companies aligning its long-term strategy with this shift.